The negotiation of a licensing and cooperation agreement between Formula Pharmaceuticals and the Helmholtz Association’s Max Delbrück Center for Molecular Medicine (MDC) is the latest in a series of commercialization successes for the MDC brokered by Ascenion. The partners will use a gene transfer system from the MDC in combination with technologies from Formula in order to develop cell-based immunotherapies.
In the past few months, the MDC has already announced two drug-development milestones in connection with its patents: a drug for the treatment of bleeding disorders developed by Baxter had been submitted for approval, and Amgen has received approval for the cancer drug Blincyto®.
You can find more information here:
<link http: www.ascenion.de _blank external-link-new-window>Press release on the agreement between Formula and the MDC